GSK has become the latest drugmaker to run into difficulties in developing a drug targeting the immune checkpoint receptor TIM-3.

The White House has confirmed that the trade deal signed with the EU – which includes an overarching tariff rate of 15% on imports into the US – does extend to most pharmaceutical products ...

AbbVie could be heading for its second acquisition in the space of a month, as rumours emerge of a $1bn bid for psychiatric drug developer Gilgamesh.

The disruption at the FDA continues with the departure of CBER director Vinay Prasad, less than three months after taking on the role.

Three key lessons the past five years of challenges and experience have taught us that we can use to move the biosimilars market forward.

Brain-computer interface firm Neuralink has completed a $650m financing that it says will help to "bring our technology to more people" ...

This month, we explore the 125-year-old history of Abbott Laboratories and its most significant milestone to date – the creation of its own independent company, AbbVie.

The recent move to introduce an “Amazon-style” prescription tracking in the NHS App is a crucial first step. People want ...

Hemlibra (emicizumab), the only treatment currently available for haemophilia A via the NHS that doesn't require an ...

In a new study, the large-language model (LLM) ChatGPT was able to reduce the time needed to review whether a patient is suitable for a clinical trial and delivered big reductions – from an average of ...

From trade associations to medtech innovators and biotech start-ups, here’s a comprehensive look at the latest boardroom ...

"For decades, bureaucrats and entrenched interests buried health data and blocked patients from taking control of their ...